2014 Handbook genesis 2014 INNOVATE DEVELOP EXPAND IN FLANDERS Meet us at the session on ‘The role and impact of nano-electronics in healthcare and life science research’ by Dr. Liesbet Lagae, Associate Professor at K.U. Leuven and Head of R&D at IMEC. IMEC is Flanders’ world-leading independent research centre for nano-electronics applied in future healthcare needs. Visit us at stand no. 31 and find out what Flanders Investment and Trade can do for you and your company!

INVESTINFLANDERS.COM Sponsors 3

Genesis 2014 Sponsors Platinum Sponsors Contents Welcome 6

Plenary Speakers 7 - 8

Speakers 8 - 21 Gold Sponsors Programme 22 - 23

Floor Plan and Exhibitor List 24 - 25

The Source Lounge 29 - 32 Silver Sponsors

Exhibitors 33 - 45

Corporate Patron

Corporate Sponsors Bronze Sponsors

INNOVATE Partners DEVELOP EXPAND IN FLANDERS Supporters Meet us at the session on ‘The role and impact of nano-electronics in healthcare and life science research’ by Dr. Liesbet Lagae, Associate Professor at K.U. Leuven and Head of R&D at IMEC. IMEC is Flanders’ world-leading independent research centre for nano-electronics applied in future healthcare needs. Media Partners Visit us at stand no. 31 and find out what Flanders Investment and Trade can do for you and your company!

INVESTINFLANDERS.COM EDINBURGH BIOQUARTER Scotland. The home of INSPIRING Whisky and the Bionic Hand.

LOCATION We’re the toast of the Edinburgh BioQuarter is an academic medical centre scientifi c community. with a focus on interdisciplinary research and translational medicine, with particular strengths in regenerative medicine and connected health. The campus brings together a clinical research imaging centre (mining population based ‘Big Data’ clinicians, industrialists, patients, housing CT/MRI/PET scanners, a GMP sets for healthcare research) and other scientists, state-of-the-art cell therapy manufacturing facility and organisations focused on data science. pre-clinical and clinical research an NHS clinical service laboratory. The BioQuarter Commercialisation facilities, and an academic There are also three MRC Centres Team, established in 2010, has since teaching hospital on one campus. on site specialising in Reproductive created more than 10 new life science Extending to more than 100 acres, Health, Inflammation Research and businesses and successfully negotiated Edinburgh BioQuarter is a £600 million Regenerative Medicine as well as a BHF industrial collaborations in excess of joint venture between Scottish Centre for Cardiovascular Medicine. £20 million. Enterprise, the University of Edinburgh Building Nine, the BioQuarter Future plans for the site include and NHS Lothian. Once fully developed, has rapidly established itself as the the construction of the Edinburgh Sick the BioQuarter will offer up to centre for commercial activity on site. Children’s Hospital, which will provide 1.4m sq ft (130,063 sq m) of specialist This three-story multiple occupancy an additional 600 patient beds and a accommodation for academic, building is now home to more than paediatric clinical trials suite, and the commercial and healthcare activity. 15 companies involved in life sciences Department of Clinical Neurosciences, We’ve got quite a reputation for invention, innovation institutions and purpose built science parks with The BioQuarter links a broad range from start-ups and support services both scheduled to open in 2017. Plans and improving people’s lives. Penicillin. Keyhole surgery. some of the fi nest research facilities in the world. of leading companies and research to major international businesses. are also being taken forward for further institutions, providing world class The current commercial tenants, university research institutes, a second The beta-blocker. The game of golf. It’s a long list. And passionate people with a hunger to win. We can facilities with one-stop access to its such as Molnlycke Health Care, multi-occupancy building for companies And it’s still growing. In every sector from fi nance and develop your products and expand your business. unique combination of pre-clinical Fios Genomics, Calcivis, Edinburgh wishing to locate on the site as well as electronics to our pioneering work in life sciences, we And that’s precisely why companies invest in Scotland. and clinical excellence. Molecular Imaging, IOmet Pharma on site hotel and conferencing facilities. strive to set standards. We have world-class academic The site currently boasts over Ltd and J&J Innovation, include 1,300 researchers, 120 academic global inward investors, cutting edge CONTACT clinicians, 960 inpatient beds, regenerative medicine companies, t +44 (0)131 242 9444 To see what Scotland can do for your business, visit www.sdi.co.uk/lifesciences 15 on-site companies, an MHRA and innovative SMEs. The building e [email protected] accredited Phase I clinical trials suite, is also home to the Farr Institute w www.bioquarter.com SCOTLAND. SUCCESS LIKES IT HERE.

SDI-32100-Whisky-Bionic-276x210-AW-GK.indd 1 01/10/2014 10:02

RC0640 Advert AW_REV.indd 1 24/09/2014 09:52 Scotland. The home of Whisky and the Bionic Hand.

We’re the toast of the scientifi c community.

We’ve got quite a reputation for invention, innovation institutions and purpose built science parks with and improving people’s lives. Penicillin. Keyhole surgery. some of the fi nest research facilities in the world. The beta-blocker. The game of golf. It’s a long list. And passionate people with a hunger to win. We can And it’s still growing. In every sector from fi nance and develop your products and expand your business. electronics to our pioneering work in life sciences, we And that’s precisely why companies invest in Scotland. strive to set standards. We have world-class academic

To see what Scotland can do for your business, visit www.sdi.co.uk/lifesciences

SCOTLAND. SUCCESS LIKES IT HERE.

SDI-32100-Whisky-Bionic-276x210-AW-GK.indd 1 01/10/2014 10:02 6

welcome Dear Genesis Participant,

Welcome to our 14th Annual Genesis Conference:

The One Nucleus team and I know you New for this year is our Source Lounge will make full use of the presentations, - do check out Page 29 for more details. debate, networking and the exhibition The Source Lounge has a dedicated hall to catch up with old friends and make space located within the main exhibition some new ones, update yourselves on hall with four hubs; Finance, Innovation, trends in the sector and create and scope International and R&D along with the out new business opportunities. Please Source Advice Group. The idea behind do not hesitate to talk with any one of the Source Lounge emerged from the One Nucleus team. We are here to delegate feedback that whilst they are help you make the most of your time at very comfortable with the use of the 1-2- Genesis and ensure you leave us with 1 meetings system to target potential a spring in your step and light of heart clients, partners or investors they know knowing that you have just had a hugely they want to meet, they sometimes leave productive day! events feeling they may have missed opportunities that weren’t initially on I know times continue to be tough their radar. We want to make sure all for many of you. As I always maintain, potential interactions are visible – so however, there have always been a do take advantage and visit the Source myriad of challenges for companies in Lounge area. this environment and you have always had to think creatively to forge ahead. The We are also continuing with the much sector has many champions, exceptional appreciated (by us and delegates) entrepreneurs and individuals who are collaboration with the SCRIP team on well placed to meet the challenges and Genesis, which saw its first ‘outing’ at continue to strengthen the sector into the Genesis 2012. We have worked incredibly future. closely together on key elements of the event, evolving it to enhance the The One Nucleus membership continues knowledge-sharing opportunities. to grow and we remain the largest The insights gained over the day will membership organisation in Europe fuel the much anticipated Plenary (by some distance, with over 470 Debate providing the panellists and organisations as members). The majority delegates with the chance to share of our members are based in Cambridge their suggestions to enhance success and London with many of them here at individual, company and sector wide today. level.

Genesis 2014 continues to be a truly Finally and very importantly I would international networking exhibition that like to extend a big ‘thank you’ to all our evolves year on year. We are delighted Sponsors, supporters and collaborators that UK Trade & Investment has chosen for helping to make Genesis happen. to repeat the success of their UKTI International Zone that we have brought I wish everyone an excellent event. in for the last three years and you will find it again this year in the Fleming Room. Commercial Officers (many of them specialists in the sector) have joined us from around the world and are ready to provide you with information, advice, contacts and ideas in the partnering zone – all free and impartial. Plenary Speakers 7

Rowan Gardner Chairman, BioLauncher

Rowan has spent her career working at the edges of life science, analytics and money and has direct experience of founding, fundraising and exiting businesses. She is a member of the SBC Experts Panel, Digital Health Forum Advisory Board member and an Astia Advisor helping women led businesses access capital. Since August this year she has been work- ing to get RowAnalytics a complex data analytics business with a focus on health off the ground.

Ken Sutherland President, Toshiba Medical Visualisation Systems

Ken currently holds the position of Company President of Toshiba Medical Visualization Sys- tems in Edinburgh with responsibility for a large team of computer scientists, data analysts and clinical experts. This group is responsible for research and development of advanced visualization technology and novel clinical applications for 3D medical imaging as part of Toshiba Medical Systems Corporation. In this post Ken is part of Toshiba Medical’s Global R&D leadership and serves as an industry advisory to the Scottish Government on the Life Sciences Industry Leadership Group (LiSAB). Ken also holds the position of Chair of the Scottish Lifesciences Association, a trade body for the industry in Scotland. Ken returned to Edinburgh in August 2007 to join Toshiba as R&D General Manager having previously held the post of Operations Director for a European multinational running its imaging R&D facility in Cambridge, England. Ken studied Electronics and Computer Science at Edinburgh University and has a PhD in image analysis and four years postdoctoral research experience in medical image analysis.

Adrian Towse Director, Office of Health Economics

Adrian’s current research includes the use of ‘risk-sharing’ arrangements between health care payers and pharmaceutical companies, including value-based pricing ap- proaches; the economics of pharmacogenetics for health care payers and the pharma- ceutical industry; economic issues that affect both R&D for and access to treatments for diseases prevalent in the developing world; the economics of medical negligence; and measuring productivity in health care.

A visiting Senior Researcher at the Nuffield Department of Population Health at the University of Oxford, Adrian also has been a Visiting Professor at the University of York. Adrian joined the OHE in 1993. 8

Mike Ward Chief Content Officer, SCRIP Intelligence and Datamonitor

Mike has been writing, analysing and commenting on the life sciences industry for the past 30 years. He has focused on business models, R&D strategies and how to finance innovation, and is often called upon by the industry’s key stakeholders to provide thought leadership. In 2010 he was named European Mediscience Commentator of the Year.

Speaker Profiles

Neil Adams Director Operations and Delivery, Medical Devices, BSI

Neil is a Regulatory Affairs professional with over thirty years’ experience. After ten years as a regulator and policy maker in UK Government, Neil has spent over twenty years working in industry and the regulatory service sector. He has been leading BSI’s medical device certification effort for six years; currently as Director Operations and Delivery, Medical Devices. He is responsible for operational and regulatory affairs aspects of the BSI medical technology organisation, including its Notified Bodies: NB 0086 in the UK and NB 0535 in Germany.

Before joining BSI Neil was European Regulatory Affairs Manager for STERIS Corporation, working on the regulatory freedom to operate of Active and Non-active Medical Devices, Disinfectants, Detergents and Cleaners, Cosmetics and other consumable products and capital equipment.

He is a member of the TOPRA Medical Technology SPIN Steering Committee, and a Vice Chairman of the Association of British Healthcare Industries (ABHI) Technical Policy Group. Neil represents BSI in negotiations with the UK Government on all aspects of medical devices regulations. The current focus is on the navigation of the proposed medical device regulation and in vitro diagnostic device regulations through the European Commission, Council of Ministers and European Parliament.

Session: Is Medical Device and IVD Regulation Moving in the Pharma Direction?

Davidson Ateh CEO, BioMoti

Davidson Ateh is a healthcare entrepreneur. He has an interdisciplinary scientific background in the physical and life sciences having completed a first degree in Biomedical Materials and a PhD in Bioengineering. He is a past recipient of the prestigious Royal Society of Edinburgh/BBSRC Enterprise Fellowship during which he had a year of business training at the endowed Hunter Centre for Entrepreneurship of Strathclyde Business School (University of Strathclyde).

Davidson has a successful track record of financing disruptive ideas and progressing new technology. He is the CEO of BioMoti that is seeking to transform the treatment of cancer using its precision immunotherapeutic nanomedine platform: Oncojans™. BioMoti’s lead candidate for the unmet ovarian cancer indication has the potential to be a groundbreaking cancer therapy for patients in need.

Session: Case Study Deal 3 - F-star Alpha Deal with BMS Speaker Profiles 9

Penny Attridge Investment Director, SPARK Impact

With a background in venture capital investment, product development and commercialisation, Penny brings a wealth of valuable experience to the SPARK Impact team.

Penny joined Quester (which was later acquired by SPARK) in 2005. She had previously worked at BTG plc where her role focused on client development, identifying and acquiring early stage inventions from academia and SMEs in the UK, which BTG then developed and commercialised.

Penny also spent many years with the Public Health Laboratory Service, and had a notable academic career with over 100 previewed publications in the field of applied medical microbiology. In addition to her role as an investment director at SPARK Impact, Penny is a founder and director of Id-Tech Ltd., a company that has successfully exploited her inventions to prevent needlestick injuries.

Session: Case Study Deal 2

Rodrigo Barnes CTO, Aridhia

Rodrigo Barnes is CTO at Aridhia, setting technology strategy for the company’s platform, including AnalytiXagility, the collaborative data science safe haven service. He has designed and developed a wide range of health informatics systems and is currently leading the development of Aridhia’s genomic medicine services. His background is mathematics and software engineering, applied over the last ten years in biomedical informatics. He manages technical partnerships and works directly with clinical research consortia and healthcare providers as customers.

Session: It’s not BIG DATA it’s DIFFERENT DATA that is the challenge in Life Sciences

Anthony Baxter CEO, Cyprotex

Dr Baxter has over 30 years’ experience in management and research in pharmaceutical and biotech- based small molecule and biologic drug discovery, medicinal chemistry services, biomolecule detection instrumentation, and ADMET contract research organisations. He has led Cyprotex PLC as CEO for 6 years successfully growing revenues, profits and staff numbers in addition to completing three acquisitions of Cellumen, Apredica and CeeTox LLC over that time. Before assuming leadership of Cyprotex in 2008, Dr Baxter was CEO (2005–2008) of deltaDOT Ltd, the founding CEO (1999-2004) of Argenta Discovery Ltd and the CSO (1994–1999) of Oxford Asymmetry. He commenced his career with Glaxo Group Research (now GSK) and Ciba Central Research (now Novartis). He also has the role of Non-Executive Chairman for Equinox Pharma Ltd and Glythera Ltd, the latter is a new company with an exciting novel linker platform to develop new and improved antibody drug conjugates (ADC’s).

Session: SCRIP-One Nucleus Debate “What Kind of Life Science Companies Should we be Building?”

Eddie Blair Managing Director, Integrated Medcines Ltd

Dr Eddie Blair is Managing Director of Integrated Medicines Ltd (IML), a company he formed in 2003 to enable personalised medicine by combining diagnostic-type testing with new and existing medicines. He is also Chief Executive of GeneFirst Ltd, a non-executive director (Rem Com Chair) of Immunodiagnostic Holdings PLC, and a visiting scholar to the Cambridge University Masters in Bioscience Enterprise programme. He also lectures on personalised medicines and offers occasional bespoke courses based on his best-selling books. He has published more than 40 primary, peer-reviewed papers, including a series on companion diagnostic valuation, and is editor of two personalised medicine journals. Finally, he is named inventor on at least one dozen patents.

Session: One Nucleus Plenary Debate 10 Speaker Profiles

Mark Blanchard Alliance Manager, Orca Partnership Ltd

Mark’s a chemist by trade with a successful 20+ year career building and nurturing productive partnerships within complex global organisations that deliver sustainable business results. His experience spans the chemical and life science industries in senior sell & buy side roles, including field sales, clinical outsourcing, supply chain development, procurement, business processing outsourcing and alliance management. He brings with him a broad & deep understanding of what good partnering looks like from many different perspectives, and what it takes to achieve it.

Session: Aligning Stakeholder Interests in External Partnerships

Ian Charles Founder and CSO, Auspherix and Director, ithree institute, UTS, Sydney Australia

Internationally renowned scientist and entrepreneur, in a career spanning academia, biotech and big pharma with an emphasis on translational research. Currently head of the ithree institute, focused on infectious disease research and microbial genomics. Co-founder and CSO of anti-infectives spin-out companies, Auspherix and, previously, Arrow Therapeutics, from the Wolfson Institute for Biomedical Research at UCL, where he was a founding member. Other positions at Sheffield and Cambridge Universities, and 10 years at the Wellcome Laboratories and Glaxo-Wellcome.

Session: SCRIP-One Nucleus Debate “What Kind of Life Science Companies Should we be Building?”

Yen Choo Founder & Executive Chairman, Plasticell Ltd and Founder & Chief Executive of Progenitor Labs Ltd

Dr Choo is Founder & Executive Chairman of Plasticell Ltd and Founder & Chief Executive of Progenitor Labs Ltd, biotech companies focused on stem cell research for the development of cell therapies and regenerative drugs, respectively. Prior to his interest in stem cells he was Founder & Chief Scientist of Gendaq (1999-2001), a zinc finger engineering company acquired by Sangamo Biosciences and whose technology is the basis of the ZFP technology platform. Previously he was a staff scientist at the MRC Laboratory of Molecular Biology, Cambridge (1995-2000), where he researched the engineering of protein-DNA interactions using combinatorial methods under Nobel laureate Sir Aaron Klug. Dr Choo holds a PhD in Molecular Biology from the University of Cambridge (1991-1995) and for his thesis received the Prize for Young Scientists awarded by GE Healthcare and Science (1996), and the Max Perutz Student Prize awarded by MRC-LMB (1995). He serves on the UK Stem Cell Steering Committee which oversees national stem cell research and the UK Stem Cell Bank (2007-). Session: Are Cell Technologies the R&D Revolutionaries?

Mary Clark Managing Director, Hume Brophy

Mary Clark joined Hume Brophy in 2013 and heads up the company’s International Healthcare IR & PR practice. Mary has over 20 years’ experience in strategic corporate and financial communications. She specialises in advising healthcare companies on all aspects of their financial and corporate communications. She has a wealth of experience in corporate positioning, M&A, IPOs and fund raisings. She has worked with over 30 healthcare clients across 10 European countries. Mary was previously Head of Healthcare at Capital MS&L. Prior to this she was Head of the European Consulting team at Thomson Reuters, the world’s largest investor relations company, where she advised a large number of companies on investor relations strategies, and all aspects of corporate and financial communications. She started her career at BTG plc where she was Director of Corporate Communications and Investor Relations. Mary has been regularly highly ranked in the top professionals in the Extel investor relations survey voted by leading institutional investors and sell-side analysts.

Session:Investing in Innovation: The Johnson & Johnson Innovation Experience Speaker Profiles 11

Bob Clay Chief Regulatory Officer, Kinapse

Bob Clay, a regulatory strategist with an extensive track record in drug development and has held senior leadership positions in regulatory affairs at several companies including Pfizer and AstraZeneca. He has led projects across a range of therapeutic areas and has a strong interest in the impact of regulation on the development of innovative medicines. Bob is currently Chief Regulatory Officer at Kinapse; a board director at TOPRA; and Managing Director at Highbury Regulatory Science.

Session: Industry - NHS Data Sharing for Collaborative Product Development

Ann Connolly Senior Director, New Ventures, Johnson & Johnson Innovation

Ann Connolly is the Senior Director, New Ventures for Johnson & Johnson London Innovation Centre. In this role she enables the company building process for early stage opportunities and is developing the early phase portfolio of opportunities for J&J

Prior to joining Johnson & Johnson, Ann was the Senior Director Business Development with UCB Pharma, where she was responsible for business development activities supporting both Immunology and CNS divisions with their early stages of development. She was also the Director of Worldwide Business Development at GSK, and supported the Respiratory franchise to complement the existing R&D portfolio, as well as supporting device licensing activities. She also has experience in Preclinical Development and was involved in progressing many programs across therapeutic sectors for SmithKline Beecham/GSK. Ann holds a PhD in Biochemical Toxicology from the University of Surrey.

Session: Investing in Innovation: The Johnson & Johnson Innovation Experience

Kevin Cox CEO, Imanova

Kevin is CEO of Imanova, a unique joint venture between the MRC and Kings, Imperial and UCL. Imanova has world-leading expertise in imaging sciences. Kevin’s has lead high-growth businesses, and worked with the NHS and academia. He is experienced in biopharmaceutical development, laboratory diagnostics, and technology translation. Kevin’s public sector roles include: Chair, UKTI’s Bio/Pharma Advisory Committee, Chair, BioNow, UK Life Sciences Marketing Strategy Board, TSB advisory board for stratified medicine, NED of the BNA and the BIA.

Session: Imaging in Drug Discovery and Development

Nick Crabb Programme Director - Scientific Affairs, National Institute for Health and Care Excellence

Dr Nick Crabb, Programme Director - Scientific Affairs, NICE: Nick had a 20 year career in analytical science, process technology and general management in the chemical, pharmaceutical and contract laboratory industries prior to joining NICE as the associate director for the new Diagnostics Assessment Programme in January 2010. Nick was responsible for the establishment and management of the programme. In 2014 Nick was appointed Programme Director for Scientific Affairs where he oversees NICE Scientific Advice and the Research and Development programme.

Session: Are Cell-Based Technologies the R&D Revolutionaries? 12 Speaker Profiles

Greer Deal Director, Global Regulatory Services

Greer Deal MCMI MTOPRA, Director of Global Regulatory Services, has an extensive career in the pharmaceutical industry. Her experience includes regulatory affairs, medical information, pharmacovigilance, product development and compassionate use programmes. Greer is passionate about plant-derived products and believes Pharma needs to ‘look back’ in order to go forward and that investors must be bold to help revolutionise this niche area of the life sciences.

Session: Is Medical Device and IVD Regulation Moving in the Pharma Direction?

Luc Dochez Chief Business Officer, Prosensa Therapeutics

Luc Dochez, has served as Prosensa’s Chief Business Officer and Senior Vice-President of Business Development since November 2008. Mr. Dochez has over 15 years of experience in the biotechnology industry. Before joining Prosensa, Mr. Dochez was a consultant within Arthur D. Little’s biotechnology practice from 1998 to 2001, Director of Business Development at Methexis Genomics N.V. from 2001 to 2002, Vice President of Business Development at TiGenix N.V. from 2002 to 2008 and President of TiGenix Inc. from 2007 to 2008. Mr. Dochez holds a Pharm.D. degree from the University of Leuven, a postgraduate degree in business economics from the same university and an M.B.A. degree from Vlerick Management School. Mr. Dochez is currently an independent supervisory board member at Ovizio S.A.

Session: Case Study Deal 2 - Prosensa-GSK Deal and Beyond

Barbara Domayne-Hayman Chief Business Officer, Autifony Therapeutics Ltd

Barbara has a broad range of commercial and general management experience. She is currently Chief Business Officer at Autifony Therapeutics, Entrepreneur-in-residence at the Stevenage Bioscience Catalyst and Acting Chairman of Puridify. Previously Barbara was CEO of Stabilitech, and before that Commercial Director of Arrow Therapeutics until its sale to AstraZeneca. Earlier positions included roles in business development at Celltech and senior international commercial positions at Zeneca. Barbara holds a Sloan Fellowship from London Business School, and has a D.Phil in chemistry, from the University of Oxford.

Session: SCRIP-One Nucleus Debate “What Kind of Life Science Companies Should we be Building?”

Chris Farmakis GLE Group

Chris is working for GLE Group, an economic intervention organisation headquartered in London with nationwide coverage in the UK and operational branches in Prague and Brussels. His role is provide support for capital functions (funding and private finance) under Enterprise Europe Network for London. He has overseen over £60m worth of private capital transactions in the form of equity investments in SMEs and more than £250m. worth of debt structuring

Session: Lunchtime Keynote Address

John Faulkes Consultant, PPMLD

John began his career as a scientist in the Wellcome Foundation (now GSK). He moved after some years to a new career in training/HR as a trainer and eventually an learning and Development Business Partner. He left to become a consultant in the 1990’s, working as a freelancer running team building sessions, personal skills courses and doing instructinal design and coordination. In 2001 he co-founded PPMD Ltd, which specialises in enhancing collaborative working in the Pharma, Biotech and related service industries. PPMLD are the preferred suppliers to the London-Cambridge based cluster One Nucleus, and also are on the Exec committee of the PIPMG (Pharmaceutical Industry Project Management Group).

Session: Aligning Stakeholder Interests in External Partnerships Speaker Profiles 13

Richard Featherstone Human Factors Director, Medical Device Useability Ltd Session: Is Medical Device and IVD Regulation Moving in the Pharma Direction?

Eliot Forster Chairman, MedCity

Dr Eliot Forster is Executive Chair of MedCity, launched by Mayor of London Boris Johnson in April 2014 to promote collaboration, entrepreneurship and investment in the life sciences sector of the London-Oxford- Cambridge golden triangle. He has over 20 years of industry experience in biotechnology and pharmaceutical companies, and is also Chief Executive Officer of Creabilis Ltd, a UK-based biotech specialising in dermatology. Prior to setting up Creabilis, he held roles including CEO of Boston-based Solace Pharmaceuticals, Head of EU Development and of Development Operations in the EU and Asia at Pfizer, and a number of non-executive posts in bioch companies. He holds a PhD in neurophysiology from Liverpool University and an MBA from Henley Management College.

Session: MedCity Breakfast Briefing

Susan Foster Partner, Mintz Levin Cohen Ferris Glovsky and Popeo LLP

Susan works with life sciences companies, primarily on licensing, collaborations, and commercial matters. Susan has assisted biotech, pharmaceutical, diagnostic, and medical device companies with licenses, collaborations, spin-offs, and agreements relating to consulting services, R&D, manufacturing, and international distribution. She has represented a broad range of clients from start-ups to international industry leaders, and has significant experience with cross-border transactions. In addition to the Life Sciences, Susan practises in the fields of clean tech, high tech, mobile media, and data protection/privacy.

Session: Case Study Deal 3 - F-star Alpha Deal with BMS

Flic Gabbay Founder/Partner, TranScrip Partners

Flic is Managing Partner of TranScrip Partners of which she was a co-founder in 2008 and has worked in the pharmaceutical industry for more than 30 years. She has held a number of senior and CEO positions in both big pharma, biotech and CROs. She is one of TranScrip’s specialists in infectious disease, respiratory and a pre and peri-registration drug safety.

Flic has held senior positions in pharma and bio-tech companies in Europe and North America and worked on a range of projects including small molecules and biologicals. She has worked on antibiotics, antifungals, respiratory, anti-inflammatories, lipid lowering agents, renal disease and oncology and has co-led many successful license applications including five she has worked on and defended within TranScrip. In 1990, Flic founded Gabbay Group, a CRO acquired by PPD where she was Global VP for Regulatory and Clinical Research. She has also been CEO of two small biotech companies, Director of Education at the Drug Safety Research Unit in Southampton and Chairman of the steering group that set-up the UK Faculty of Pharmaceutical Medicine (FPM) and, for nine years, was its Academic Registrar.

Session: Aligning stakeholder interests in External Partnerships

David Gauden Head of Development, Blue Earth Diagnostics

David Gauden is the Head of Development in Blue Earth Diagnostics. Prior to joining Blue Earth he was Product Leader for oncology molecular imaging in GE Healthcare, with business responsibility for the portfolio mix, licensing, product development and strategic marketing activities for a range of developmental PET drugs. Now 20 years in the medical imaging industry, David has deep expertise across the business spectrum. He held roles of increasing seniority within supply chain, project management, IP licensing and clinical development. David has an undergraduate degree from the University of Warwick and a doctorate in Biochemistry from the University of Oxford.

Session: Imaging in Drug Discovery and Development 14 Speaker Profiles

Hakan Goker MS Ventures

Hakan Goker, PhD, joined MS Ventures in 2013. Previously, Hakan was a partner at Aescap Venture in Amsterdam which he joined in 2010. Prior to Aescap, he was at Atlas Venture in London until their cessation of European operations. He was instrumental in the creation and financing, in addition to, business and R&D strategy of various companies including Orphazyme-DK, f-Star NL, Protaffin- Austria/UK, Bicycle Therapeutics -UK, Nimbus Discovery -US, Lumavita -CH, Nitec now Horizon Pharma -CH/US, and Egalet -DK. In addition to the UK, US, Benelux and Switzerland, his global investment and deal flow experience includes the geographies of Scandinavia and Asia. Hakan received his Ph.D. in oncology from the Institute of Cancer Research/ University of London, UK and continued his scientific career with post doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his B.Sc. Hons, from University College London.

Session: Case Study Deal 3 - F-star Alpha Deal with BMS

Shaun Grady Vice President - Strategic Partnering & Business Development, AstraZeneca

Accountabilities: Vice President Business Development Operations; leading AstraZeneca’s transaction execution, due diligence and Alliance and Integration Management function including early and late stage and on-market licensing and partnering, M&A, and divestments. Career background: ICI, Zeneca, AstraZeneca roles in Corporate, Pharmaceuticals and US Legal departments, HR and Business Development. Major Projects: AZ Merger, Creation of Avecia and Syngenta, Acquisition of CAT, MedImmune and Amylin, Spin out of Albireo

Session: Case Study Deal 1- AstraZeneca-BMS Diabetes Alliance (continued)

Enda Gribbon Atelix Ltd

Atelix is a proponent of inclusive partnering at all stages and levels, to develop a vibrant biopharma sector. Recent transactions supported have been within the neuroscience, inflammation, oncology, med-tech and vaccines fields.

Some academic entrepreneurs introduced Enda to the world of biotech and start-ups, from where it was possible to experience the real-time convergence of the scientific and commercial disciplines. Subsequent roles within mid-sized specialty pharma and international biopharma organisations enabled an understanding of both “buy-” and “sell-side” perspectives and the mutual imperatives for durable partnerships. Supporting Genesis affords the opportunity to reinvigorate such ideals as the bio-community reflects on 2014’s achievements and sets fresh goals for the New Year.

Session: Case Study Deal 2 - Prosensa-GSK Deal and Beyond

Roger Gunn CSO, Imanova

Roger Gunn is Chief Scientific Officer at Imanova, which is a joint venture between the three major London universities (Imperial, UCL, Kings) and the MRC that was established in 2011 to provide high end R&D imaging capabilities to London academia and Big Pharma. Roger is also Professor of Molecular Neuroimaging in the Division of Brain Sciences at Imperial College London and Visiting Professor at the University of Oxford.

Session: Imaging in Drug Discovery and Development

John Haurum CEO, F-Star

John Haurum joined F-star as the CEO in May 2012. Previously he was VP Research at ImClone Systems, New York (2010-2012). Before then he was the Chief Scientific Officer and cofounder of Symphogen A/S, Denmark (2000- 2009). After graduating in Medicine in Aarhus Denmark 1992, Dr. Haurum received a D.Phil. in Immunology from the Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, England. Subsequently, he took up a position as Associate Professor at the Danish Cancer Society and completed his medical training.

Session: Case Study Deal 3 - F-star Alpha Deal with BMS Speaker Profiles 15

Kurt Hertogs Head of Platform Innovation & Incubator Strategy Leader, Johnson & Johnson Innovation

Kurt Hertogs is the Platform Innovation & Incubator Strategy Leader at Johnson & Johnson Innovation Centre London. In this role, he is responsible for leading the development and implementation of a European incubator strategy in collaboration with regional stakeholders. Kurt is the primary liaison between internal expertise and the broader life science ecosystem in key regional hubs, focusing on strategies that can most effectively translate academic science into innovative new products. Kurt previously held research and early stage development roles at Tibotec and was involved in the discovery and pharmacological profiling of major anti-infective drugs like Prezista, Intellence, Edurant, Incivo and Simeprevir. From 2008 onwards, he has led the European and Global Enabling Research Capabilities at Janssen R&D, and has aided in the discovery product portfolio across Janssen’s five therapeutic areas. In this capacity, he was a member of the Janssen R&D Senior Leadership Team and the Janssen R&D Operational Management Committee. Kurt is a trained Pharmacist and holds a PhD in Pharmaceutical Sciences from the Catholic University of Leuven. He is a member of the Board of Directors of Janssen Pharmaceutica NV.

Session: Investing in Innovation: The Johnson & Johnson Innovation Experience

Urban Hoglund CEO, Adlego Biomedical Session: Case Study Deal 1- AstraZeneca-BMS Diabetes Alliance (continued)

David Jeffreys Senior Vice President, Eisai

Dr Jefferys is currently the Senior Vice President for Global Regulatory, Healthcare Policy and Corporate Affairs, Eisai Europe and Chairman of the Eisai Global Regulatory Council. He also sits as a member of the European Working Group of the UK Ministerial Industry Strategy Group and UK Innovation Board. He is Chairman of the ABPI Regulatory Affairs Group and a member of several EFPIA committees. Also co-chairman of the IFPMA RPTS.

Session: Is Medical Device and IVD Regulation Moving in the Pharma Direction?

Declan Jones VP, Neuroscience Innovation, Johnson & Johnson Innovation

Declan Jones is Vice President, Neuroscience Innovation at the London Innovation Centre, where he is responsible for identifying neuroscience drug discovery and development opportunities from European academic and biotech labs, particularly for Alzheimer’s disease and Mood Disorders. Declan previously worked for GlaxoSmithKline’s Centre of Excellence for External Drug Discovery (CEEDD) where he was responsible for creating scientific strategies and managing processes from preclinical to Phase II state programs across all therapeutic areas. Prior to CEEDD, he spent nearly 14 years in neuroscience drug discovery and development within GSK. Declan was the recipient of an R&D Pipeline award in 2009 for his leadership of a schizophrenia program with a successful Phase II outcome. Declan has over 75 peer reviewed publications and external presentations and served as core panel member for Neuroscience on the BBSRC grant committee for a 3 year term. He received his PhD from the University of Bradford and did post-doctoral work at Emory University and University of Hertfordshire before joining the pharmaceutical industry.

Session: Investing in Innovation: The Johnson & Johnson Innovation Experience

Roy Katso Innovation Challenge Manager, Bioelectronics R&D, GSK Session: Think Small for Big Changes

Jim Kinnier-Wilson Partner, Penningtons Manches

Session: Case Study Deal 2 16 Speaker Profiles

Leisbet Lagae R&D Manager, IMEC & KU Leuven

IMEC is a world-leading independent research center in nanoelectronics and nanotechnology headquartered in Leuven, Belgium with staff of more than 1650 people including 550 industrial residents and guest researchers. IMEC’s research bridges the gap between fundamental research at universities and technology development in industry. Prof. Liesbet Lagae, Ms. E. E., Phd. received her degree from the KU Leuven, Belgium for her work on fast switching of Magnetic Random Access Memories in 2003. After her PhD, she started a new research team that pioneered the field of lab-on-chip and molecular biochips based on magnetic, optical and electrical sensing principles and that grew tremendously since its foundation in 2006. The Life Science Technology department currently has a head count of 70 people, and performs R&D on miniaturized lab on chip systems in collaboration with several major companies. Liesbet Lagae is still the scientific R&D manager of the department. She has (co-) authored more than 100 peer-reviewed papers in international journals and holds 15 patents and applications in the field. She holds an ERC consolidator grant as of 2014 as indication of her Scientific Leadership. She is also part-time professor in nanobiotechnology at KU Leuven and director of IMEC’s Academy Bioschool.

Session: Think Small for Big Changes

Birger Larsen Aalborg University

Birger Larsen is Full Professor in Information Analysis and Information Retrieval at the Department of Communication, Aalborg University Copenhagen (Denmark). He has a passion for research that involves the activities, processes and experiences arising in the meeting between users, information, and information systems in a given context - with the goal of optimising these to empower users in their task and problem solving. His main research interests include Information Retrieval (IR), Digital Humanities and Bibliometrics.

Session: An Evidence-Backed IP Strategy

Stephen Little CEO, Premaitha Health

Stephen is a successful serial biotechnology entrepreneur. He is the former CEO of DxS, an innovator in the field of personalised medicine, developing and manufacturing companion diagnostics. DxS was funded with £3.5M in 2001 and was sold to QIAGEN BV in 2009 for £85M. DxS pioneered the use of molecular diagnostic tests such as KRAS and EGFR mutation analysis to predict the use of novel cancer therapies. In 2009, DxS was acquired by QIAGEN and Stephen became Vice President of Personalised Healthcare, responsible for developing companion diagnostic partnerships with the pharma industry. Prior to his leading role at DxS, Stephen worked for 20 years in various senior positions in the diagnostic divisions of Astra Zeneca and ICI. He holds a PhD from Heriot-Watt University in Edinburgh.

Session: SCRIP-One Nucleus Debate “What Kind of Life Science Companies Should we be Building?”

Kit Malthouse Deputy Mayor of London for Business and Enterprise, Greater London Authority

In Boris Johnson’s second term as Mayor (May 2012-2016), Kit Malthouse is the Deputy Mayor with responsibility for promoting London businesses, jobs, apprenticeships and economic growth, and is London’s spokesperson on economic issues. He is a qualified accountant and runs several of his own businesses. After completing his degree in politics and economics at Newcastle, Kit qualified as a Chartered Accountant. In 1998 he was elected to Westminster City Council. Kit was then elected as Deputy Leader of the Council and was appointed Cabinet member for Finance. During the five years he remained in this job he increased council reserves by more than £50m and delivered one of the lowest council tax levels in the country.

He was elected to the London Assembly on 1 May 2008, representing the West Central Constituency (Kensington and Chelsea, Hammersmith and Fulham and Westminster boroughs) and was appointed Deputy Mayor for Policing and Chair of the Metropolitan Police Authority in October 2008. Following Kit’s and Boris’s re-election on 3 May 2012, Kit took up his current position as the Mayor’s chief aide on business matters. In August 2013 he was appointed as Chair of London and Partners, which is the city’s official promotion and inward investment agency.

Session: Keynote Address Speaker Profiles 17

Maggie Massam Head of Business Development, CPRD Session: It’s not BIG DATA it’s DIFFERENT DATA that is the challenge in Life Sciences

Stephen Minger Chief Scientist, GE Healthcare

Dr Stephen Minger was appointed the Global Director for Research and Development for Cell Technologies at GE Healthcare in September 2009. Stephen received his PhD in Pathology (Neurosciences) in 1992 from the Albert Einstein College of Medicine in New York City. After post-doctoral work in central nervous system gene therapy, neural transplantation and neural stem cell biology at UCSD he moved to the UK in 1996 and was appointed a Lecturer in Biomolecular Sciences at King’s College London in 1998. He was appointed a Senior Lecturer in Stem Cell Biology in 2005 and was the Director of the Stem Cell Biology Laboratory from 2002 until joining GE Healthcare in 2009. Stephen is currently the Chief Scientist for Cellular Sciences, GE Healthcare Life Sciences, and is responsible for long-term global research strategy for technology development in cell therapy, regenerative medicine, cellular technologies, in vivo diagnostic imaging and molecular pathology/personalised medicine.

Session: Are Cell-Based Technologies the R&D Revolutionairies?

David Morley VP, Computational Technology, Ariana Pharmaceuticals

Dr. Morley is an experienced computational technologist with a 20 year track record in managing the development of high-performance machine learning solutions to “big data” scientific challenges across multiple industries, including pharma, chemical and finance. David started his career at Eastman Kodak before joining RiboTargets where he was the architect and project manager of RiboDock/rDock, a production virtual screening platform for structure-based drug discovery. He has been involved with Ariana and their KEM® platform since 2004.

Session: Case Study Deal 1- AstraZeneca-BMS Diabetes Alliance (continued)

Stephen Parker CEO, Structured BioEquity Inc

Stephen is CEO of Structured BioEquity Inc., a New York-based start-up providing risk management solutions to development-stage biotech companies. He was previously a partner with the Celtic Pharma funds from 2005-2014. He has over 25 years experience in working with and in the pharmaceuticals and biotech sectors, as a strategic consultant, investment banker and corporate officer, including CFO of Oxford GlycoSciences, where he raised £170m in a follow-on round and NASDAQ listing and led the creation of the personalised medicine joint venture, Confirmant, with Marconi plc..

Session: Case Study Deal 1- AstraZeneca-BMS Diabetes Alliance (continued)

Robert Perneczky Co-Head of Department, Imperial College London

Robert Perneczky received his MD and PhD degrees from Technical University Munich and worked as a Consultant Psychiatrist in Munich before he was appointed as Reader in Cognitive Impairment and Dementia as well as Co-Head of Department at Imperial College London’s School of Public Health in 2013. His research focuses on the early diagnosis of cognitive disorders such as Alzheimer’s disease, including imaging, biomarker and genetic studies. He was awarded an MBA degree from Warwick Business School in 2014.

Session: Imaging in Drug Discovery and Development 18 Speaker Profiles

David Phillips Partner, SR One

David joined SR One in 2008 to pioneer a new function to incubate and spin-out technologies from GSK and subsequently joined the team focusing on European investments. David brings a range of experience to SR One, including senior management roles in sales and marketing, commercial strategy and business development at Glaxo Wellcome, Cephalon, Medical Venture Management, The Automation Partnership and Galapagos. David has significant deal making experience in the pharmaceutical and biotech sectors and has run a number of successful businesses deriving healthy exits for investors. David has a BSc (Hons) in Pharmacology from the University of London and is a member of the Charted Institute of Marketing. David is based in London.

Session: SCRIP-One Nucleus Debate “What Kind of Life Science Companies Should we be Building?”

Jennifer Pierce Partner, Charles Russell Speechlys

Jennifer Pierce is a partner at Charles Russell Speechlys and heads its commercial intellectual property group. She advises on IP protection and strategy together with all forms of IP and commercial agreements relating to life sciences. She is included in IAM’s global list of patent and technology licensing specialists. Jennifer began life sciences work at BTG, where she advised on licensing and was a member of the team that floated the company. Since returning to private practice, she has worked with a variety of life sciences organisations, ranging from major pharmaceutical licensing companies to spin-outs to Governmental organisations.

Session: Case Study Deal 1- AstraZeneca-BMS Diabetes Alliance (continued)

Rob Pinnock Director Scientific Liason, Merck

Rob joined MSD’s licensing team in Sept 2007 and since mid 2008 his remit is to identify partnering opportunities in the UK, Ireland, Portugal & Spain. Before joining MSD Rob worked for a year in Cambridge University on neuronal injury & prosthetics. He spent time in Biotech between 2004-6, advancing programs in CV, metabolic disease & pain from concept to clinic. Previously he held positions of increasing seniority in Parke Davis, Cambridge, UK, until their acquisition by Pfizer. In 2001 he moved to Pfizer research laboratories in Ann Arbor, Michigan, as senior director for CNS Molecular Science. Collaborations were an important part of Rob’s mandate at Parke-Davis / Pfizer. Before he joined the pharmaceutical industry Rob trained in Southampton & spent several years as a research fellow at the MRC and University of Cambridge.

Session: Are cell technologies the R&D Revolutionairies?

Thomas Plath Director Business Development, ICON Clinical Research

Thomas is Director Business Development at ICON clinical research, a full service CRO and leading medical imaging service vendor. Thomas works for more than 10 years in medical imaging and clinical research in different imaging CROs. He is a trained biochemist with many years of pre-clinical research in academia and Biotech. He managed more than 30 medical imaging studies and gained significant experience in CNS clinical studies: e.g. Alzheimer´s disease, stroke, glioblastoma, brain haemorrhage.

Session: Imaging in Drug Discovery and Development

Paul Quinlan Operations and Open Innovation Director, Unilever Session: An Evidence-Backed IP Strategy

Jane Reed Linguamatics Session: It’s not BIG DATA it’s DIFFERENT DATA that is the challenge in Life Sciences Speaker Profiles 19

Ton Rijnders Science Director, TI Pharma

Ton Rijnders holds a PhD in molecular biology. He joined Organon in 1986 and became Vice President Research in 2003. In 2007 Ton was appointed VP Discovery and Site Head Oss within the Schering-Plough Research Institute. After the merger with Merck Ton continued to head Discovery in Oss within the Merck Research Labs until 2011. In 2011 Ton has taken up responsibility as Scientific Director at TI Pharma. As of 2013 Ton is also Head of the European Screening Centre, part of the IMI European Lead Factory.

Session: Aligning Stakeholder Interests in External Partnerships

Philippe Roguenda Inhalation Asia

Philippe Rogueda is an experienced R&D executive with a track record of driving business growth within the pharmaceutical industry. Key strengths include: a deep knowledge of developing markets particularly China and the Far East; driving innovative drug delivery from concept to registration; developing innovation growth to enable emerging companies to become global industry players; defining milestones and targets to translate research aspirations into deliverable projects; and utilising personal international networks to deliver commercial success.

Session: An Evidence-Backed IP Strategy

Felicity Sartain Director, NanoScientium

Felicity is a Co-founder and Director at NanoScientium. She is a Chemist with 10 years of managerial, commercial and research experience in the life sciences, med tech and clean tech. Felicity was the Programme Director at Bio Nano Consulting, delivering client nanotechnology projects, developing market and business opportunities and securing global contracts. Felicity also led the Healthcare and Life Sciences Theme for the Nanotechnology Knowledge Transfer Network (KTN), supporting the exploitation and commercialisation of micro and nanotechnologies across the UK. She was a co-inventor of the original technologies at Smart Holograms, a Cambridge University spin-out that designed and developed novel biosensors and prior to this worked in Research and Development at GSK where she developed microfluidic drug discovery platforms. Felicity holds an MChem in Chemistry with Life Sciences and Pharmaceuticals from the University of York, and a PhD from the University of Cambridge. Felicity is a Member of Royal Society of Chemistry, the Nanomedicine Focus Group Leader at the Academy of Pharmaceutical Sciences and a STEMNet Ambassador.

Session: Think Small for Big Changes

Robert Shaw Vice President, Commercial Development, Progenitor Cell Therapy

Robert (Bob) Shaw joined Progenitor Cell Therapy (PCT) in 2013 as Vice President, Commercial Development. He is tasked with enhancing PCT’s growth through strategic transactions and additional business lines, as well growing the existing Client base through enhanced technical sales and marketing initiatives. Over the last two decades Bob has held several positions at EMD Millipore Corporation including Commercial Director – Stem Cell Initiative.

Session: An Evidence-Backed IP Strategy

Jonathan Stewart Consultant, Pain Medicine Imperial College NHS Healthcare Trust

Dr Jonathan Stewart is an anaesthetist who has held posts as a Consultant in the NHS and led Pain Research teams at Pfizer, GSK and BMS. His main interests are in novel clinical trial designs and ensuring access to patients of new medicines where there is clear unmet medical need. Dr Stewart has experience in Regulatory Submissions, Health Technology Assessments and Drug Safety.

Session: Industry - NHS Data Sharing for Collaborative Product Development 20 Speaker Profiles

Quentin Tannock Chairman, CambridgeIP

Quentin Tannock is an intellectual property (IP) strategy consultant and is Chairman of CambridgeIP - the leading global innovation and IP consultancy.

Quentin and CambridgeIP have significant IP strategy and IP Landscape® experience within the Health and Life Sciences domain. Quentin’s IP strategy work has been featured by the BBC, the Financial Times, Nature Publishing Group and other leading media.

Quentin is also a co-inventor on University of Cambridge originated nanotechnology and biomedical diagnostics patents.

Session: An Evidence-Backed IP Strategy

Abel Ureta-Vidal CEO, Eagle Genomics

With over 15 years bioinformatics experience and a scientific background in molecular biology and immunovirology (PhD from the Pasteur Institute, France), Abel first got to grips with bioinformatics tools and code in the early 90s whilst working on viral phylogenetic studies.

After his PhD, he joined the effort in ramping up the Human Genome Project at Genoscope (Evry, France), putting in place the automatic gene annotation system for human chromosome 14. In 2001, he moved to the European Bioinformatics Institute (Cambridge, UK) where he led the Ensembl comparative genomics team until 2007 under Ewan Birney leadership. In 2008 he founded Eagle Genomics shortly before graduating from the Cambridge Judge Business School MBA program.

For the last six years he has been one of the driving forces within the executive team at Eagle, supporting the strategy and partnership activities as well as setting up a world-class company operation able to adapt to market demand. This has enabled the company to sustain its growth and extend its activities horizontally from the traditional pharma/biotech sector into sectors as diverse as plant breeding, animal health, consumer goods and food safety.

Session: It’s not BIG DATA IT’S DIFFERENT DATA that is the Challenge in Life Sciences

Johan Verbeeck Senior Director, Johnson & Johnson Innovation

Johan is Senior Director, Partnership Management at J&J Innovation London. Johan graduated as Doctor in Veterinary Medicine at the University of Gent, Belgium in 1994 and joined Janssen Pharmaceutica in Belgium in 1996 in the Department of Animal Health. In 1998 Johan began working in Toxicology as Study Director for a multitude of small molecule development projects. In 2003, he graduated cum laude as Master of Science in Applied Toxicology at the University of Surrey, UK.

In 2005, Johan joined Tibotec and as Director of Toxicology, he was Lead Toxicologist for the development of Prezista and Intelence, Tibotec’s first two approved anti-HIV drugs. At the same time he was Preclinical Development Leader for Bedaquiline, the first new drug in development for tuberculosis in over 40 years. Based on his previous expertise with the compound, Johan was an active contributor to the successful Advisory Committee meeting on Bedaquiline and its subsequent FDA approval. In 2013 Johan was a recipient of the Johnson Medal – the most prestigious award given for research and development within Johnson & Johnson – for his role on the team that developed SIRTURO™ (bedaquiline, TMC207).

In 2007, after the approval of Intelence, Johan transferred to North America to become Head of Toxicology Sciences for Janssen at the Raritan, New Jersey site. In 2011, he became Alliance Manager in the External Alliances and Business Models group. In January 2013, Johan relocated back to Europe to work in his current role with Johnson & Johnson Innovation, London.

Session: Investing in Innovation: The Johnson & Johnson Innovation Experience Speaker Profiles 21

Elaine Warburton CEO, QuantuMDx

Elaine received an OBE in 2014 for services to innovation in healthcare. An entrepreneur with over 25 years’ healthcare and biotechnology experience, with an eclectic background in nursing, genetics, accounting and running hospitals. She is CEO of British biotech QuantuMDx, developers of a handheld molecular diagnostic lab with DNA sequencing capabilities to address humanitarian health challenges and detect & track emerging pandemics. Infectious disease & drug susceptibility assays will be commercialised in 2016.

Session: Think Small for Big Changes

David Williams Director, Medico-Market Access

Dr David Williams - Director Medico-MarketAccess and CMO Lifecode, UK based consulting firm, delivering a unique combination of medical, healthcare and policy insight and high level analytical and Health Economic capability. Prior to this role, he has had broad pharmaceutical medical affairs in GSK, Boehringer Ingelheim and Shire and healthcare experience, including Head of Corporate Government Affairs and Public Policy at AstraZeneca and leadership roles in HEOR. A qualified physician for 24 years and master’s graduate in HEcon and EBM.

Session: Industry – NHS data sharing for Collaborative Product Development

One Nucleus Training One Nucleus have a portfolio of training courses designed to help life science and healthcare companies build an experienced and cohesive workforce. Our tailored training courses are based on the needs of our member companies and we are constantly developing courses on new subjects as our members’ needs change.

Silver members receive a discount on list prices and Gold members receive enhanced discounts plus priority booking.

01223 896455 onenucleus.com/courses www.onhelix.com 22 Programme

08.00 Registration

08.00 - 09.00 MedCity Breakfast Briefing - Albert Suite, 2nd Floor Eliot Forster Chair, MedCity

09.00 Opening of Genesis 2014 Whittle Room

09.00 - 09.10 Welcome from One Nucleus Harriet Fear CEO, One Nucleus

09.10 - 09.20 Introduction from the Chair Eddie Blair Integrated Medicines

09.20 - 09.45 The Economics of Risk-Sharing and Personalised Medicine Adrian Towse Office of Health Econmics

09.45 - 10.10 Big Data Innovation for Better Health Outcomes Ken Sutherland Toshiba Medical Visualisation Systems

10.10 - 10.35 2014 Winners and Losers Mike Ward SCRIP Intelligence and Datamonitor

10.35 - 11.00 Bah Humbug! The Ghost of Pharma’s Christmas Future Rowan Gardner BioLauncher

11.00 - 11.30 Coffee break

11.30 - 12.30 Parallel sessions I

St James Suite, 4th floor Westminster Suite, 4th Floor Victoria Suite, 2nd Floor Albert Suite, 2nd Floor Case Study Deal 1 - It’s not BIG DATA it’s Imaging in Drug Discovery Is Medical Device and IVD AstraZeneca-BMS Diabetes DIFFERENT DATA that is the and Development Regulation moving in the Alliance (continued) challenge in Life Sciences Pharma direction?

Chair Chair Chair Chair Mike Ward Abel Ureta-Vidal Kevin Cox Greer Deal SCRIP Intelligence Eagle Genomics Imanova GRS Plenary Speaker Plenary Speaker Plenary Speaker Shaun Grady Kevin Cox Neil Adams AstraZeneca Imanova BSI Group

Panellists Panellists Panellists Panellists Urban Höglund Rodrigo Barnes Roger Gunn Richard Featherstone Adlego Biomedical Aridhia Imanova Medical Device Usability Ltd

Jennifer Pierce David Robertson Robert Perneczky David Jefferys Charles Russell Speechlys University of Edinburgh Imperial College London Eisai

David Morley Thomas Plath Maggie Massam Charlotte Teall Ariana Pharmaceuticals ICON Clinical Research CPRD Forresters Stephen Parker David Gauden Jane Reed Structured BioEquity Inc Blue Earth Diagnostics Linguamatics

12.30 - 14.00 Lunch

12.45 - 13.05 Keynote Address Chris Farmakis GLE

13.05 - 13.35 BioNewsRound 2014 Award Presentation Whittle Room Programme 23

14.00 - 15.00 Parallel sessions II

St James Suite, 4th floor Westminster Suite, 4th floor Victoria Suite, 2nd Floor Albert Suite, 2nd Floor Case Study Deal 2 - MRCT Industry - NHS Data Sharing Are Cell-Based Technologies An Evidence-Backed IP and Yabao Pharmaceuticals for Collaborative Product R&D Revolutionairies? Strategy Development

Chair Chair Chair Chair Michael Dalrymple Bob Clay Stephen Minger Quentin Tannock MRC Kinapse GE Healthcare Life Sciences CambridgeIP Plenary Speaker Stephen Minger, GE Healthcare Life Sciences Panellists Panellists Panellists Panellists Penny Attridge David Williams Rob Pinnock Philippe Roguenda SPARK Impact Medico-Market Access Merck Inhalation Asia Enda Gribbon Jonathan Stewart Nick Crabb Birger Larsen Atelix Imperial College NHS Healthcare National Institute for Health and Care Aalborg University Trust Jim Kinnier-Wilson Yen Choo Robert Shaw Pennington Manches Plasticell and Progenitor Progenitor Cell Therapy

Paul Quinlan Simon Bennett Unilever SBA Ltd

15.00 - 15.30 Coffee break

15.30 - 16.30 Parallel sessions III

St James Suite, 4th floor Westminster Suite, 4th floor Victoria Suite, 2nd Floor Albert Suite, 2nd Floor Case Study Deal 3 - F-star Investing in Innovation: Aligning Stakeholder Think Small for Big Changes Alpha Deal with BMS The Johnson & Johnson Interests in External Innovation Experience Partnerships Technologies and Support Chair Chair Chair Felicity Sartain Mike Ward Mary Clark Chair NanoScientium SCRIP Intelligence Hume Brophy John Faulkes PPMLD Plenary Speaker Plenary Speaker Leisbet Lagae John Haurum Plenary Speaker IMEC & KU Leuven Ton Rijnders F-Star TI Pharma Panellists Panellists Panellists Panellists Roy Katso Hakan Goker Ann Connolly Mark Blanchard GSK MS Ventures Johnson & Johnson Innovation AstraZeneca Elaine Warburton Davidson Ateh Kurt Hertogs QuantuMDX BioMoti Flic Gabbay Johnson & Johnson Innovation TranScrip Partners Sue Foster Declan Jones Mintz Levin Cohen Ferris Glovsky Johnson & Johnson Innovation and Popeo LLP Johan Verbeeck Johnson & Johnson Innovation

16.35 - 16.45 Introduction to the European MediScience Awards 2015 Whittle Room Jo Thomas European MediScience 16.45- 17.45 SCRIP - One Nucleus Plenary Debate: What Kind of Life Science Companies Whittle Room Should we be Building? Mike Ward David Phillips Anthony Baxter Steve Little Barbara Domayne-Hayman Ian Charles Geraldine O’Keeffe SCRIP Intelligence SROne Cyprotex Discovery Premaitha Autifony Therapeutics Auspherix Life Science Partners 17.45 - 18.00 Keynote Address Kit Malthouse Whittle Room Deputy Mayor of London for Business and Enterprise

18.00 - 19.00 Drinks reception

Exhibitor List 25

48 A4P Bio 18 Pharmidex 40 Alzheimer’s Research UK 37 Public Health England 19 Andrew Porter Ltd 27 QuickSTAT 43 APL 22/23 R.G.C.C. International GmbH 42 AstraZeneca 2 RiverRhee Consulting 5 Bio-Rad AbD Serotec Ltd 20 Sahlgrenska Science Park 47 BioReliance 58 SBRI 26 Boyd Consultants Ltd 33 SCRIP Intelligence 29 Cogent 25 Scottish Development International 54 CryoStore Ltd 17 Sequani Ltd 51 Discovery Park 4 Stockholm-Uppsala Life Science (SULS) 55 Dora Wirth (Languages) Ltd 62 Source Lounge - Finance hub 41 Dundee Cell Products 64 Source Lounge - Innovation hub 30 Eagle Genomics 65 Source Lounge - International hub 24 Edinburgh BioQuarter 61 Source Lounge - MedCity 38 ERA Consulting 63 Source Lounge - R&D hub 35 firstsightmedia 28 TranScrip Partners 31 Flanders Investment & Trade 13 UKBIF 32 Flemish Representation 3 UKTI 11 Forresters 34 UMI3 14 GLE 36 United Airlines 59 Health Enterprise East 12 United Life Sciences 46 Illingworth Research 8 Venture Valuation 53 KISS Communications 44 World Courier 45 Mathys & Squire 7 NIHR Office for Clinical Research Infrastructure 52 Nova Language Services Ltd 57 Pharma Publications 21 Pharmaceutical Training International

    Eagle_A4 Base.qxp_Layout 1 17/11/2014 17:24 Page 1

eaglegenomics.com does your scientist speak genomics? The Source Lounge 29

The Source Lounge brought to you by

The Source Lounge at Genesis supported by MedCity (Stand 61), is a dedicated space located within the main exhibition hall with four hubs. The idea behind the Source Lounge emerged from talking with organisations about conferences, who say that whilst they are very comfortable with the use of the 1-2-1 meetings systems to target potential clients, partners or investors they know they want to meet.

International Hub Sponsored by Flight Centre Business Travel Stand 65 ` and Occams

This will be a focal point in the Source Lounge for those already undertaking or seeking to undertake, business internationally. Providing insight and tools to locate potential partners, investors and clients globally as well as assistance and savings on flights, hotels and conferences whilst developing those opportunities. The groups below will be specifically represented at the conference and the specified delegates can be targeted for 1-2-1 meetings through the online partnering facility: Companies profiled at the Finance Hub include: UBIFRANCE, Occams, Flight Centre Business Travel (FCBT), Stockholm Uppsala Life Sciences (SULS), Flanders Investment & Trade (FIT), e-Learning for Life Sciences internationalisation (eLSi) EBD and Biopartner.

R&D Hub Sponsored by Hartswood Media Stand 63 Source R&D is the new directory where life science companies can discover and learn about relevant CRO and CMOs to partner with in their research and development projects. Companies profiled at the R&D Hub include: 42 Technology, ABS Laboratories, Abzena (Antitope and Polytherics), Abcodia, AMS Biotechnology (Europe) Limited, Domainex, Isogenica, KWSBioTest, Sygnature.

Innovation Hub Sponsored by New Scientist Stand 64 Offering the latest news, ideas and opinions, New Scientist is an authoritative voice on all matters related to science, technology and the ideas improving our knowledge of the universe and those shaping our world and lives. We aim to make science accessible to anyone, but are also highly regarded amongst students, graduates, researchers and scientists seeking inspiration, careers advice and opportunities in STEM fields. Companies profiled on the Innovation Hub include: Aston University, Babraham Institute Enterprise Ltd, Guy’s and St Thomas’ NHS Foundation Trust, Imperial Consultants, The University of Oxford and Oxford University Hospitals NHS Trust.

Finance Hub Sponsored by Hume Brophy Stand 62 This will be a focal point in the Source Lounge for those seeking information and guidance on accessing finance, whether European or National grant schemes, private capital or public markets. The groups below will be specifically represented at the conference and the specified delegates can be targeted for 1-2-1 meetings through the online partnering facility. Companies profiled at the Finance Hub include: Alzheimer’s Research UK, European Lead Factory, Innovate UK. Catalysing the power “The alchemy that turns of the golden triangle discoveries into new therapies and technologies is capital” Kit Malthouse, London’s Deputy Mayor for Business and Enterprise

From the Francis Crick Institute and the Early-stage life sciences companies offer Cell Therapy Catapult to Imperial West and exciting opportunities for investors to make AstraZeneca’s Global R&D Centre, the life excellent returns and make a difference to sciences constellation of the London-Oxford- the health and well-being of thousands. Cambridge golden triangle is in a period of unprecedented ambition. Angels in MedCity runs regular free workshops for potential investors to understand the sector, Established by the Mayor of London with the identify strong propositions and connect with capital’s three academic health science centres, angel syndicates led by sector experts. MedCity is championing entrepreneurship and investment to build on the region’s global Angels in MedCity is a partnership between MedCity, London Business Angels and Angels4LifeSciences. The programme reputation as a world-leading life sciences cluster. is devised and delivered by London Business Angels.

Find out how we can help you do Find out more about opportunities for business across the south east of England investors and emerging companies at medcitylondon.com angelsinmedcity.org.uk

MedCity_Adverts_Genesis_Conference_v4.indd All Pages 04/11/2014 16:36 Catalysing the power “The alchemy that turns of the golden triangle discoveries into new therapies and technologies is capital” Kit Malthouse, London’s Deputy Mayor for Business and Enterprise

From the Francis Crick Institute and the Early-stage life sciences companies offer Cell Therapy Catapult to Imperial West and exciting opportunities for investors to make AstraZeneca’s Global R&D Centre, the life excellent returns and make a difference to sciences constellation of the London-Oxford- the health and well-being of thousands. Cambridge golden triangle is in a period of unprecedented ambition. Angels in MedCity runs regular free workshops for potential investors to understand the sector, Established by the Mayor of London with the identify strong propositions and connect with capital’s three academic health science centres, angel syndicates led by sector experts. MedCity is championing entrepreneurship and investment to build on the region’s global Angels in MedCity is a partnership between MedCity, London Business Angels and Angels4LifeSciences. The programme reputation as a world-leading life sciences cluster. is devised and delivered by London Business Angels.

Find out how we can help you do Find out more about opportunities for business across the south east of England investors and emerging companies at medcitylondon.com angelsinmedcity.org.uk

MedCity_Adverts_Genesis_Conference_v4.indd All Pages 04/11/2014 16:36 Dates for your Diary 2015

JAN BioWednesday Social JUL BioWednesday 07 London 08 LBIC, London

JAN Network Meeting Social JUL ON Helix 28 Cambridge 14 Wellcome Trust Conference Centre, Hinxton Hall, Cambridge

FEB BioWednesday JUL M11 Med Tech Forum 04 Queen Mary BioEnterprises, London 22 Harlow

FEB Life Science Leadership Series SEP 12 BioWednesday ‘Immunotherapy in Cancer’ 02 Olswang, London Babraham Research Campus, Cambridge

MAR BioWednesday SEP 04 Network Meeting CambridgeIP/Rainmaking Loft, London 16 Deloitte, Cambridge

MAR M11 Med Tech Forum SEP Life Science Leadership Series 18 ‘Strategies and Funding of Clinical Trials’ Harlow 24 Chesterford Research Park, Cambridge

MAR Network Meeting OCT BioWednesday 25 Cambridge Airport, Cambridge 07 Instinctif, London

APR Network Meeting OCT Network Meeting 29 Taylor Vinters, Cambridge 14 Marks & Clerk, Cambridge

MAY BioWednesday OCT M11 Med Tech Forum 06 Charles Russell Speechlys, London 21 Harlow

MAY Life Science Leadership Series NOV BioWednesday 20 ‘Anti-Microbial Resistance’ 11 Chesterford Reseach Park, Cambridge Queen Mary BioEnterprises, London

JUN BioWednesday NOV Network Meeting 03 EIP, London 25 Stevenage Bioscience Catalyst

JUN Network Meeting Summer Social DEC Genesis 30 Granta Park, Cambridge 10 QEII, London Exhibitor Profiles 33

A4PBio provide CRO oversight, project Alzheimer’s Research UK is Europe’s Andrew Porter Limited is a laboratory management and consultancy services leading research charity for Alzheimer’s relocations specialist and the only company in order to deliver regulatory compliant and other dementias. Since 1992, we in the sector in Europe to adopt GxP bioanalysis and bio-logistics solutions to the have committed over £53m to over 430 standards. The need to relocate equipment life science sector. A4PBio offer client-focused world-class dementia research projects is integrated with the movement of solutions in global laboratory selection, at leading universities across the UK. We temperature controlled materials, data and through assay development and validation, fund biomedical research to understand dangerous goods as part of an overall lab study sample analysis, data reporting and the causes of dementia, improve diagnosis, relocation package. The firm understands document review. Combining this with and to develop effective treatments and the post move IQ/OQ/PQ requirements, bespoke logistics solutions for the pro-actively preventions . In addition, we help people with every move focused toward the most managed transport of time and temperature to understand dementia and the progress efficient and effective uptime sequencing critical biological samples and cell-based being made through research, and forge requirement. therapies. A4PBio’s flexible and scalable partnerships with government and other key With its fleet of more than 60 vehicles, resources, using considerable Pharmaceutical, organisations to make dementia research a the firm provides professional support Biotechnology and CRO experience, deliver national and global priority. to organisations operating across the individually built, cost effective, scientifically European life sciences landscape, as well as robust and regulatory compliant outsourcing www.alzheimersresearchuk.org/ further afield using its extensive network of or consultancy solutions. [email protected] worldwide partners. Rosa Sancho, Research Knowledge Manage Ian James, CEO Stand 40 John Best, European Sales Director [email protected] [email protected] www.a4pbio.com www.andrewporterltd.co.uk Stand 48 Stand 19

APL is a leading Contract Development AstraZeneca is a global, innovation- Bio- Reliance is a leading contract services and Manufacturing Organisation within driven biopharmaceutical business that company in the area of product safety. Our Scandinavia. We have been established for focuses on the discovery, development and areas of expertise include complete and over 30 years with four production sites in commercialisation of prescription medicines, comprehensive Genetic Toxicology resources, Sweden that offer services that cover the primarily for the treatment of cardiovascular, with predictive screening, GLP assays, tier II entire development process. We specialise metabolic, respiratory, inflammation, mechanistic assays and paradigms to follow up in both sterile and non sterile manufacturing autoimmune, oncology, infection and positive results. We also are the leading provider of biopharmaceuticals and pharmaceuticals neuroscience diseases. AstraZeneca operates of testing for transgenic carcinogenicity along with drug product formulation in over 100 countries and its innovative assessment and offer complementary services development and analytical method medicines are used by millions of patients including LC/MS analysis, clinical pathology, development. APL is highly flexible, we are worldwide. For more information please visit: and cutting-edge R&D developing new also very dedicated to our customers and we www.astrazeneca.com and innovative assays. Our clients include can help you with a small project right up to pharmaceutical, biotechnology, chemical, manufacturing your product. Our facilities consumer product, medical device and are fully cGMP compliant and are regularly academic organisations. BioReliance is a inspected by EMA, FDA, customers corporate specialised provider, focusing in niches of QA. excellence, allowing for dedicated and superior [email protected] delivery of services. www.astrazeneca.com Mattias Nystrom, Business Development Stand 42 www.bioreliance.com/ Manager Stand 47 [email protected] Stand 43 Patent and Trade Mark Attorneys

We make it our business to understand yours

Clear, straightforward advice for all your intellectual property issues

Birmingham : +44 (0) 121 236 0484 Liverpool : +44 (0) 151 255 2180 London : +44 (0) 20 7283 8989 Munich : + 49 (0) 89 2441 299 0 email : [email protected] website : www.forresters.co.uk Exhibitor Profiles 35

AbD Serotec, a Bio-Rad company, is Boyd Consultants was established in Cogent The Cogent Group comprises an expert manufacturer and supplier of 2005 and provides a range of expertise Cogent SSC, The Cogent Technical antibodies for drug discovery, clinical and skills central to the development of Apprenticeship Service and The National diagnostics and academic research. Whether pharmaceutical & biotechnology medicinal Skills Academy for the Process Industries. you need a ready-made product, a complex products and medical devices. Cogent Group Companies work in an custom antibody generation project, or We are based in the UK with offices located alliance with employers to develop, design small to bulk manufacturing and purification in Cheshire and Cambridgeshire. and deploy skills and education solutions for services, we cater for all requirements. No Our consultancy services offer a cost- the science industries. other company can rival our unique custom effective solution for those requiring expert The approach is evidence-based and recombinant monoclonal antibody service assistance in order to expedite development, employer-led, with the ambition to that generates highly specific, high affinity add value to their product, and reach those boost sector innovation, growth, and Fab antibodies with >90% success rates in milestones. competitiveness through skills. Cogent only 8 weeks. We aim to help you reach your Professional Services Group skills solutions are adopted by every goals by providing the antibodies you need • Product Development size of organisation, from SMEs through to and a professional, long-term partnership for • Regulatory Affairs global companies. Cogent works right across success. For further information visit www. • Regulatory Medical Writing the science sector including life sciences and abdserotec.com. • Statistics and Data Management industrial science. • Medical Monitoring Support Paul Royle - Commercial Services Consultant • Business Support [email protected] • Training Kate Hutchins [email protected] www.abdserotec.com Prof Alan Boyd, CEO www.cogent-ssc.com Stand 5 [email protected] Stand 29 www.boydconsultants.com Stand 26

Cryo-Store is a dedicated facility for the Discovery Park is Europe’s leading DWL is a specialist translation service storage of biological material, disaster science and technology park, based on provider for the pharmaceutical industry recovery material and research libraries the outskirts of Sandwich, Kent. The park providing translation solutions, in a wide in a totally secure temperature controlled is an Innovation Cluster where companies range of languages for both traditional and conditions. It provides an invaluable resource and organisations are encouraged to work emerging markets and clinical trial sites, in for the biotechnology, pharmaceutical and together and share information. Providing the fields of: medical industries. world class facilities, Discovery Park has REGULATORY AFFAIRS, Our storage temperatures range from attracted a host of international companies CLINICAL RESEARCH, ambient to liquid nitrogen. from the life science, pharmaceutical, PHARMACOVIGILANCE, The facility is GxP compliant and is biotechnology, science and technology MEDICAL RESEARCH, continuously monitored and alarmed, sectors. Facilities include research and MANUFACTURING, ensuring sample temperatures are development laboratories and specialist MEDICAL DEVICES, consistently maintained. Full emergency niche manufacturing facilities, commercial MEDICAL PUBLISHING AND back-up systems are constantly on stand by, office space, start up zone and warehouse MARKETING COMMUNICATIONS. covering storage units, power supply and solutions. Discovery Park benefits from With over 50 years of experience, DWL has data. Enterprise Zone status. developed a solid, trustworthy and cost- Cryo-Store is licenced by The Human Tissue effective service. Authority (HTA) and for the storage of GMM. Anna Stone Samuel J. Wirth, Managing Director Malcolm Wilkinson www.discovery-park.co.uk Kim Shouler, Business Development [email protected] Stand 51 Director www.cryostore.co.uk [email protected] Stand 54 dwlanguages.com Stand 55 DISCOVER THE FRENCH DELEGATION

International Hub – Stand 65 – Benjamin Britten Room

UBIFRANCE, the French agency for international development, promotes trade between France and the rest of the world, offering its clients a diverse range of customised services. Each office within the international network has specialised Trade Advisors working in various sectors to assist French companies with their commercial development strategies abroad. UBIFRANCE UK will be present at the 2014 edition of GENESIS on the International Hub (stand 65) in the Benjamin Britten room, with a delegation of French life sciences companies looking to meet potential partners in the United Kingdom.

Contact: Katie Docwra, Trade Development Adviser, Healthcare and Biotechnology Sector [email protected]

For our programme of events visit our website: http://www.ubifrance.com/uk Exhibitor Profiles 37

Eagle is an expert provider of bioinformatics Edinburgh BioQuarter is a unique Dundee Cell Products Ltd (DCP) is consultancy across a wide range of concept, bringing together scientists from a dynamic and innovative bioreagents commercial sectors, covering human the University of Edinburgh and NHS Lothian and life science services company that health, plant sciences, food, animal health, with commercial research companies to commercialises high quality research tools and consumer products. Through its collaborate and accelerate the development for biochemistry, molecular biology and cell multidisciplinary team headquartered in of new drugs, diagnostic tools and medical biology research and provides services in Cambridge, UK, Eagle can provide innovative devices to treat diseases. This enterprise these areas to the life sciences community, and proven end to end solutions to support has made Edinburgh a leading European including researchers in the pharmaceutical all of your bioinformatics research needs. destination for translational medical industry, biotechnology companies as well The Eagle team are experts in a range of research. 6 years ago the University joined as in academic research institutions. Key bioinformatics tools for both the commercial forces with Scottish Enterprise and NHS proteomics-based technologies dedicated and academic sectors, and are able to Lothian to create the Edinburgh BioQuarter. to assist the development of safer drugs provide an impartial opinion on the most Its aims were to foster deeper links with quicker include ToxProfile, BioMarkId, effective approach for your problems. As industry through collaborative research; to PhosProfile and TargetId and are delivered well as the application of bioinformatics create new companies based on Edinburgh’s through Dundee Cell Proteomics a division tools and technologies, Eagle is active in research base, and to encourage a culture of of the company. developing and improving them through commercialisation in the NHS and among a number of commercial and academic academic researchers. An experienced Dr Paul Ajuh (CEO) or Dr Chloe Steels, collaborations, such as Ensembl, Taverna and Commercialisation Team was established Account Manager & Technical Specialist TraitTag. Eagle’s client base covers the globe, in 2010 to deliver these aims and in just customerservices@dundeecellproducts. including Europe, US and the Far East. over three years has spun out seven new com DISCOVER THE life sciences businesses and negotiated a [email protected] number of major industrial collaborations, www.dundeecellproducts.com Richard Holland, CBO as well as generating 100 new product Stand 41 [email protected] FRENCH DELEGATION www.eaglegenomics.com or business concepts from its Innovation Stand 30 Competition. Shona Cameron, Head of Marketing and Communications [email protected] www.bioquarter.com International Hub – Stand 65 – Benjamin Britten Room Stand 24

ERA Consulting has served the firstsitemedia are a video production biopharmaceutical industry for over 25 company that will help you to reach your years providing regulatory, strategic and customers and target an audience with a technical guidance for the development of message that engages and informs. medicinal agents (>450 to date), including For over 20 years we have delivered creative UBIFRANCE, the French agency for international development, recombinant protein/antibody therapeutics, live event, training and promotional video promotes trade between France and the rest of the world, offering its vaccines, ATMPs (cell/tissue/gene therapies), productions and as a result have built up an Flanders Investment and Trade is a clients a diverse range of customised services. Each office within the natural products and small molecules. Our experienced and dedicated team of media government development agency at the international network has specialised Trade Advisors working in consultants are drawn from biotech, pharma, professionals who pride themselves in Belgian Embassy in London. We provide biomanufacturing, regulatory, translational exceeding client requirements. confidential expert advice on doing business various sectors to assist French companies with their commercial medicine and academic scientific Online is our forte and we excel at live on the European continent. Our services are development strategies abroad. UBIFRANCE UK will be present at the backgrounds to provide experienced and on-demand video streaming. This is tailored to your business needs and are free 2014 edition of GENESIS on the International Hub (stand 65) in the support from product inception through enhanced for conferences and webinars of charge. We can help you find the right Benjamin Britten room, with a delegation of French life sciences development to commercialisation. Services through our bespoke presentation location and get you in touch with the right offered also include regulatory training companies looking to meet potential partners in the United Kingdom. software iPresenter, allowing us to deliver specialist or partner. Flanders Investment and specialist due diligence. With offices high definition video of your speaker and Trade will guide you through our tax in London, Washington D.C, Germany and simultaneously with their presentation slides incentives and available grants to maximise Contact: Katie Docwra, Trade Development Adviser, Australia, ERA maintains a global presence across the internet. opportunity. Feel free to contact us on and interacts closely with European, US and Healthcare and Biotechnology Sector Please visit our website which contains [email protected] or +44 (0)207 307 other regulatory authorities. many examples of our work together with 77 10 regarding any query on doing business [email protected] testimonials supporting the services we in Europe. Adam Levy, Business Development provide. [email protected] Mike Gilham Business Development Geert De Proost, Representative of the www.eraconsulting.com For our programme of events visit our website: Manager Government of Flanders Stand 38 http://www.ubifrance.com/uk [email protected] [email protected] www.firstsightmedia.co.uk www.flanders.be/london Stand 35 Stand 31 Go further, faster

Enterprise Europe Network London The route to new markets new funding new ideas www.een-london.co.uk || [email protected] || +44 (0) 20 7940 1512 Exhibitor Profiles 39

Flanders House At Forresters, we provide clear, sensible GLE Enterprise Europe Network is your Flanders is a dynamic and prosperous region and practical advice on intellectual property, gateway to competitiveness and innovation. within Belgium, in the heart of Europe. As including patents, trade marks, designs and The Network supports businesses to a devolved nation, Flanders has a lot of copyright, in the UK and across the world. make the most of the opportunities autonomy and responsibilities, like in the We like to take a collaborative approach with in the European market. We help local field of health care, economic development, our clients, drawing on their knowledge to organisations to find the right business research and innovation policies. Flanders ensure that we understand what they want partners, build their innovation capacity and belongs to the top when it comes to health to achieve. meet their capital requirements. care and new technologies. Flanders’ Care, We look to deliver our guidance in plain, Enterprise Europe Network is strong of our overarching strategy for the health jargon-free language and are not afraid to approximately 600 business support care sector, aims to constantly upgrade recommend a particular course of action, if organisations in 54 EU and non-EU countries, our care system through innovation and we think it is right for you. promoting international cooperation locally. entrepreneurship. No wonder that Flanders We have a well-established and sizeable Our services are specifically designed for is a leading life sciences region with several life-sciences department, with extensive Small and Medium-sized Enterprises (SMEs) life sciences hubs. Today, biotech companies, experience in getting and litigating patents but are also available to all businesses, research centres and bio incubators in the UK and Europe. research centres and universities across flourish in state of the art science parks Europe. clustered around our largest universities. Charlotte Teall Like previous years and with the support of [email protected] the Representation of the Government of Chris Farmakis, EC Funding Manager www.forresters.co.uk Flanders in the United Kingdom (Flanders [email protected] Stand 11 House), several Flemish universities and www.een-london.co.uk research centres are present at Genesis Stand 14 to showcase their work and look for collaborations with British partners. Nic Van der Marliere, Representative of the Government of Flanders [email protected] www.flanders.be/london Stand 32

Illingworth Research is a leading KISS is a creative communications european clinical research organisation agency built on the principle of keepings (CRO) providing a full range of clinical things simple. Simple is better. In an ever development services, we are experts in increasingly complicated world it’s needed trial and investigator site management, more than ever. As a multi-disciplinary clinical monitoring and clinical trial Health Enterprise East Limited is a agency with deep experience in the life administration as well as offering some leading NHS Innovation Hub committed to science sector our services include strategy unique services to the CRO package such improving healthcare through supporting and messaging workshops, branding, as medical photography and research the development of innovative new design, advertising, digital, exhibitions, nursing services. We support the global products and services which meet the bespoke communications, training and, healthcare, biotechnology, medical device needs of the NHS. Health Enterprise East in conjunction with our partner Zyme and international pharmaceutical industries delivers a broad range of services to NHS Communications, specialist life science PR as well as other CROs. These services can organisations, providing expert advice, and marketing. funding and support to NHS innovators to be for complete service from first in man, www.kisscom.co.uk translate their ideas into practice. proof of concept studies through to post www.zymecommunications.co.uk Operating within the NHS, Health Enterprise marketing or ancillary support services for an Stand 53 East also provides consultancy services to established clinical trial. technology-based companies looking to access the UK healthcare market. John Illingworth, Managing Director Chris Armstrong, Marketing Manager [email protected] [email protected] www.illingworthresearch.com www.hee.org.co.uk Stand 46 Stand 59 40 Exhibitor Profiles

Mathys & Squire has over 100 years of NIHR Office for Clinical Research Nova Language Services Ltd is your experience in providing Intellectual Property Infrastructure (NOCRI) The NIHR one stop multilingual communication and services to UK industry. Our attorneys work Office for Clinical Research Infrastructure interpretation services provider. From clinical across a number of technical disciplines, (NOCRI) is a unique resource for the global trial protocols to marketing authorisation including biotechnology, pharmacology, life sciences industry, helping research dossiers, our expertise and specialised healthcare & medical devices, and chemistry. partners to navigate their way through the knowledge ensure we deliver the highest We have a global track record in securing research environment in this country and to levels service in over 100 languages valuable Intellectual Property rights for establish mutually beneficial collaborative worldwide. NOVA is ISO 9001:2008 and EN universities, government, start-ups and partnerships with the NIHR’s clinical research 15038 certified. Nova provides the following spin-out companies. Our attorneys also infrastructure. services covering all therapeutic fields specialize in freedom-to-operate and due NOCRI works to improve the quality, such as Oncology, Neurology, Psychiatry, diligence activities, and we are particularly efficiency and success of translational Respiratory, Cardiology : proud of our extremely high success rate research and enables this by providing: 1. Translation: Certified quality process with in both defending and challenging patents • fast and easy access to the UK’s clinical specialised native linguists. before the European Patent Office. Most research infrastructure 2. Back Translation: Always separate from the importantly, we develop IP strategies that • rapid connection to expert investigators original translators. align with our clients’ commercial plans. and cutting edge technologies and; 3. Content validation • a managed process for collaborative 4. Linguistic validation. Dr William Johnson, Associate research. 5. Label and packaging translation and [email protected] adaptation to local regulations. www.mathys-squire.com If you would like to know more about how 6. Website and software localization Stand 45 NOCRI helps establish industry-infrastructure (e-forms). collaborations, please visit www.nocri.nihr. 7. On-demand telephone interpreting. ac.uk Arun Mathew, International Sales Ravi Chana, Business Development Executive Manager [email protected] [email protected] www.nova-transnet.com www.nocri.nihr.ac.uk Stand 52 Stand 7

Pharma Publications is a dynamic media organisation, specialising in dedicated publications for the Life Sciences Industry. With a product portfolio of publications like, IPI - International Pharmaceutical Industry, JCS - Journal for Clinical Studies Pharmaceutical Training International Pharmidex provides high quality and JPC - Journal for Patient Compliance, we (PTI) is a global interactive training partner experimental preclinical ADMET/PK data, look into the best practice in outsourcing committed to the personal progression critical to drug discovery programme management for the Pharmaceutical & of aspiring life science professionals. We progression. We have comprehensive Bio-Pharmaceutical Industry. Providing provide up-to-date and topical courses, in house laboratory facilities as well as peerreviewed articles and analysis on addressing the latest concerns facing bioanalytical laboratories at the Stevenage drug discovery, drug development, clinical the pharmaceutical, medical device BioScience Catalyst. Extensive in-vitro & research, manufacturing, packaging, supply and biopharmaceutical industries. PTI in-vivo assay options enable the provision chain management, patient adherence is dedicated to improving the skills of of tailored studies to meet individual project and health outcomes, we provide professionals throughout the life cycle needs. Through extensive knowledge comprehensive guidelines to help the of a product with courses aimed at R&D, of drug discovery and development, industry grow. We endeavour to be your Regulatory Affairs, Clinical, Manufacturing Pharmidex has been able to deliver a high one-stop-shop for all your marketing to the and Business Strategy. All of our courses are level of customer satisfaction and forge industry. CPD certified and delivered as public open several strategic international alliances, courses, customised in-house courses, live focussing on operations in the following Orsolya Balogh, Central Administrator webinars and online through e-learning. areas: in vitro ADMET, in life, Pharmacology, [email protected] Our programmes are delivered worldwide CNS Drug Discovery, Bioanalysis, Metabolite www.ipimediaworld.com, www.jforcs. and have the flexibility to train small teams Identification and Bioimaging. com, www.jforpc.com to larger organisations across multiple Stand 57 countries. Alexander Pearce, Product Manager Stand 18 [email protected] www.pti-global.co.uk/ Stand 21 Exhibitor Profiles 41

Public Health England is an executive For over 30 years, QuickSTAT has played RGCC Pharma is one of the members of agency of the Department of Health. We a critical role in managing clinical trial the RGCC group, is located in Bristol, UK, and operate a nationwide, integrated public logistics for all phases of research and holds all the rights of the new developed health service through a network of over drug development. We specialise in global pharmacophore agents and candidate 5000 staff, working with and alongside shipping of time and temperature-sensitive drugs. The company, in collaboration with others to protect and improve the clinical research samples, investigational the other members of the group, analyses public’s health and wellbeing and reduce drugs, clinical trial supplies, and dangerous multiple biological samples, identifies inequalities. goods. repeatable patterns of proteins that may be Public Health England combines the Our long-standing clients include the related with the disease development and microbiology, diagnostics, research and leading pharmaceutical, biotech and clinical validates them. According to the location manufacturing capabilities of the former trial supply companies, CROs and central of the drugable target the company will Health Protection Agency with expertise labs around the world. proceed to develop either of a monoclonal in cancer and other aspects of health Our specialists are available 24/7, delivering antibody or a small molecular weight improvement and intelligence. complex logistical solutions and expert organic molecule with inhibitory properties. We aim to be the authoritative national knowledge for your clinical trials. So far the pipeline includes agents related to voice and expert service provider for public QuickSTAT has invested in leading edge, stemness as well as cancer cell metastases. health ensuring everyone is protected from client-centric technology, uniquely designed threats, providing products and services and to support clinical trial logistics. working in partnership with the industry to deliver innovative healthcare solutions. [email protected] Business Development Department Gurmeet Sidhu, Business Development Dr. Roger Oakes [email protected] [email protected] 0044 (0) 1179058738, 0044 (0) www.gov.uk/phe Sarah Elliott, Business Development 1172305034 Stand 37 [email protected] Stand 22 and 23 [email protected] http://quick.aero/quickstat Stand 27

The Small Business Research Initiative RiverRhee Consulting is committed to for Healthcare (SBRI Healthcare) is an helping teams in the Life Sciences make the NHS England initiative, championed by the most of their time and expertise. Sahlgrenska Science Park assist Academic Health Science Networks (AHSNs), We offer in-house and off-site training, entrepreneurs and innovators in creating whose role is to promote UK economic coaching and consultancy to help you: the best possible start for their promising growth by spreading innovation and best - Build and develop your team life science venture. The success factor is the practice across the NHS. - Deliver quality customer service way we tailor our support to your needs in Part of Innovation Health and Wealth, the - Enhance your management skills terms of: SBRI Healthcare programme sets industry - Simplify and streamline your processes • Business development the challenge in a series of health related - Ensure that your business changes succeed • Competences competitions which result in fully funded Our consultants have 30+ years’ experience • Networking development contracts between the coaching leaders and creating high • Financing awarded company and the NHS. While performance teams in Pharma and Biotechs. • Internationalisation the public sector has the right to license Our One Nucleus courses include • Creative environment the resultant technology, the intellectual Supervisory Training, Introduction to • Laboratory space property (IP) remains with the company, Management, Conducting Effective thereby enabling successful businesses to Performance Reviews and Appraisals, and Our remit is to continue to strengthen and grow. Smart Working for Business Growth and develop an international and attractive Innovation. Centre in the field of Life Science. Chris Armstrong, Marketing Manager Stand 20 [email protected] www.hee.org.co.uk www.riverrhee.com Stand 58 [email protected] Elisabeth Goodman, Owner and Principal Consultant Stand 2 42 Exhibitor Profiles

Scottish Development International SCRIP Intelligence - vital pharmaceutical Sequani is a preclinical CRO based in is the economic development agency for industry ideas and global signals for your Ledbury (UK) that has an international Scotland and is a joint venture between the career, your business and your future. reputation for excellence in the field of Scottish Government, Scottish Enterprise SCRIP Intelligence subscribers receive toxicology. Established for over 40 years, and Highlands & Islands Enterprise. a glimpse of the future from the daily with key areas of expertise such as First- Since it was founded 11 years ago, SDI has drumbeat of crucial events across the in-Man (Phase I) enabling programmes, transformed Scotland’s economic outlook, sector spectrum – from biotech start-ups to Reproduction Toxicology and Juvenile attracting some of the world’s biggest multinational giants; research boutiques to Toxicology, across many therapeutic companies to locate in the country, growing generic manufacturers; and suppliers large indications and to support each stage of Scottish exports and creating over 19,000 and small. clinical drug development. new jobs. Experienced writers and analysts are based Scotland hosts one of the largest life in key geographic markets to convey all Being a small/medium-sized facility of science clusters in Europe with significant aspects of the industry. Global hot topics approximately 180 people, we take a flexible international presence in research, such as orphan diseases, personalised and creative approach to drug development, development and manufacturing. With a medicine, and management strategies from working closely with our customers to long and remarkable history of medical and developed to emerging markets are covered design bespoke, tailored pre-clinical scientific discovery stretching back 200 years, with local depth and insight. programmes to meet their specific clinical Scotland has always been at the forefront of objectives. medical innovation. [email protected] Kerry Johnson, Business Development www.scripintelligence.com/freetrial Executive Fiona Jefferson, International Senior Stand 33 [email protected] Executive www.sequani.com [email protected] Stand 17 www.sdi.co.uk Stand 25

Stockholm-Uppsala is the region where TranScrip Partners is a rapidly growing UK Trade & Investment is the government business and research thrive! Our region cutting-edge contract organisation that department that helps UK-based companies is a hot-bed of creative cross-disciplinary supports biopharmaceutical product succeed in the global economy. We also help collaboration and, together, we are building development and life cycle management. overseas companies bring their high-quality international businesses and delivering real TranScrip Partners are strategic thinkers investment to the UK’s dynamic economy, research breakthroughs that will help solve who do, and doers who think strategically. acknowledged as Europe’s best place from the world’s health problems. We’re open- Working for more than 80 companies across which to succeed in global business. UK minded and productive. Our state-of-the-art 4 continents, TranScrip has shown it can Trade & Investment offers expertise and infrastructure and talented scientists provide play a crucial role in facilitating the selection contacts through its extensive network of all the services and support you’ll need. and progression of drug candidates into specialists in the UK, and in British Embassies www.suls.se clinical studies and on to POC, including and other diplomatic officers around the demonstration of potential value, and, Ola Björkman world. We provide companies with the tools where necessary, securing funding and [email protected] they require to be competitive on the world regulatory approvals. TranScrip’s expertise Ywonne Bölja stage. further extends across the design and [email protected] implementation of clinical development Stand 4 Matt Newman, Senior Sector Manager plans, risk management, regulatory and [email protected] product differentiation strategies. www.ukti.gov.uk Paul Branthwaite, Senior Partner Stand 3 Paul.branthwaite@transcrip-partners. com www.transcrip-partners.com Stand 28

SAVE THE DATE

THURSDAY 11 JUNE 2015 PAVILION AT THE TOWER OF LONDON, EC3

The European Mediscience event is integral to the progress of Europe’s Life Science sector and you can be part of this prestigious event in the following ways:

• Host a table of ten at the event (subject to availability)

• Advertise in the brochure that is distributed to all 500 attendees

• Sponsor an award or the menu (subject to availability)

• Nominate a client or company (self nominations are also welcome)

• Participate in the Marketing and PR campaign

KEY DATES: • Nominations open: 2 March 2015 • Nominations close: 15 April 2015 • Voting panel: 30 April 2015 • Shortlist announced: 1 May 2015 • European Mediscience Awards: 11 June 2015

www.mediscience-event.co.uk @EuroMed_Awards #ema Search: European Mediscience Awards

_1_EMA_A4 advert.indd 1 19/11/2014 13:25:07 Exhibitor Profiles 45

UK Bio-Incubators offer flexible laboratory United Life Sciences was formally UMIP® is The University of Manchester’s and office space, scientific and business launched in October 2014. The founder agent for intellectual property support services to early stage and growing members are One Nucleus, the BIA, Bionow commercialisation. UMIP’s three operational life sciences companies. and BioPartner. Between them these four teams: Scouting; IP Development and The UK Bio-Incubator Forum (UKBIF) is a organisations have over 1000 life science Partnering; and Enterprise and Business collection of Bio-Incubators located across and healthcare members across the UK and Development are responsible for identifying, the UK. The forum exists to promote the further afield. ULS is a strategic partnership protecting and commercialising the Bio-Incubators, share best practice and co- between them and sees them meeting at University’s IP. UMIC® is the University’s ordinate support for the life sciences early least every quarter face-to-face but also in Innovation Centre-its bioscience incubators stage business community. between, to discuss and work together on include the successful Manchester a range of important matters and initiatives Bioscience Incubator and the Core Miranda Knaggs, Chair affecting both their members and the wider Technology Facility (CTF). UMIC® also T: 01438 906 905 UK sector. United Life Sciences was formally provides conferencing and meeting room [email protected] launched in October 2014. The founder facilities. UMIP® and UMIC® are divisions of www.ukbioincubation.com members are One Nucleus, the BIA, Bionow The University of Manchester Innovation Stand 13 and BioPartner. Between them these four Group Ltd. organisations have over 1000 life science and healthcare members across the UK and [email protected], www.umip.com further afield. ULS is a strategic partnership [email protected], www.umic.co.uk between them and sees them meeting at Stand 34 least every quarter face-to-face but also in between, to discuss and work together on a range of important matters and initiatives affecting both their members and the wider UK sector. Stand 12

Valuation Services: Venture Valuation is a world leader in providing global, independent valuation and assessment services of technology-driven World Courier companies. Our focus is in Life Sciences Incorporated in 1969 World Courier is the (biotechnology, pharmaceutical, and largest and most experienced specialty medical technologies. courier with a network of over 152 Global Biotechgate database: company-owned offices, all ISO certified Venture Valuation developed, manages and GxP compliant. World Courier has set and maintains the proprietary Biotechgate the benchmark for Bio-Pharmaceutical, Database. Biotechgate is a comprehensive, time-sensitive transportation and is global life sciences database, with company the acknowledged leader in delivering profiles, licensing deals and investor customized temperature-controlled information. It provides our clients with solutions to the international bio- the most up-to-date industry intelligence. pharmaceutical industry. With in-house Our current subscribers include Pharma, scientists to understand your needs World Investors, Biotech and Medtech companies, Courier can recommend, supply and CRO / CMO, Service Providers and replenish packaging and refrigerants to Government Agencies. ensure the integrity of your temperature- The exportable database contains over controlled shipments. Documentation and 30’000 company profiles, 1600 licensing regulatory requirements are managed to deals with financial information and 3500 ensure your shipment complies with local active life sciences investors. requirements. We are dangerous-goods, Dry-Ice, liquid-Nitrogen and controlled- www.venturevaluation.com substance specialists. www.biotechgate.com Stand 8 David Spillett, Business Development Manager , Biopharm Services [email protected] www.worldcourier.com Stand 44 UK Trade & Investment (UKTI) is the Government Department that helps UK-based companies succeed in the global economy and assists overseas companies to bring their high-quality investment to the UK.

The Life Sciences Organisation (LSO) is a dedicated unit of UKTI offering trade support to UK companies and to companies seeking to export from the UK. The LSO is a catalyst for investment into the UK from the earliest R&D collaborations through to clinical trials, commercial operations and partnerships.

Businesses benefi t from the specialist support of the LSO and also from the opportunity to use the UK as a launch pad to other international markets, whether in Europe or beyond. The UK’s excellent reputation in research, clinical development, health regulation, and health economics combined with the LSO’s own global connectivity in British Embassies and other diplomatic offi ces around the world mean that the UK can help businesses maximise their export and investment potential.

Come speak to our expert advisors at Stand 3 in the Fleming Room, opposite the UKTI International Partnering Zone. Linking you to UK Life Sciences A new UK Life Sciences web portal has been launched to provide a single access point to the UK life sciences landscape. It provides an online platform to allow UK and international companies, academia and R&D organisations to connect. One of the key features of the site is access to a database of 5,000 UK life science companies that are developing, producing and marketing products and services in the pharmaceutical, medical technology and medical and industrial biotechnology markets.

To fi nd out more visit www.gov.uk/ukti/lso Twitter @UKTI_LSO

GTi223_Advert_2_0.indd All Pages 27/10/2014 16:02 UK Trade & Investment (UKTI) is the Government Department that helps UK-based companies succeed in the global economy and assists overseas companies to bring their high-quality investment to the UK.

The Life Sciences Organisation (LSO) is a dedicated unit of UKTI offering trade support to UK companies and to companies seeking to export from the UK. The LSO is a catalyst for investment into the UK from the earliest R&D collaborations through to clinical trials, commercial operations and partnerships.

Businesses benefi t from the specialist support of the LSO and also from the opportunity to use the UK as a launch pad to other international markets, whether in Europe or beyond. The UK’s excellent reputation in research, clinical development, health regulation, and health economics combined with the LSO’s own global connectivity in British Embassies and other diplomatic offi ces around the world mean that the UK can help businesses maximise their export and investment potential.

Come speak to our expert advisors at Stand 3 in the Fleming Room, opposite the UKTI International Partnering Zone. Linking you to UK Life Sciences A new UK Life Sciences web portal has been launched to provide a single access point to the UK life sciences landscape. It provides an online platform to allow UK and international companies, academia and R&D organisations to connect. One of the key features of the site is access to a database of 5,000 UK life science companies that are developing, producing and marketing products and services in the pharmaceutical, medical technology and medical and industrial biotechnology markets.

To fi nd out more visit www.gov.uk/ukti/lso Twitter @UKTI_LSO

GTi223_Advert_2_0.indd All Pages 27/10/2014 16:02 London’s premier Life Science & Healthcare networking conference genesis 2015

10 December 2015 Queen Elizabeth II Conference Centre Westminster, London, UK

genesisconference.com